R01 CA90759: The Effects of Lycopene on High Risk Prostatic Tissue
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention
Tissue Biomarkers
We will use conventional immunohistochemistry and computer-based image analysis to test the hypothesis that the lycopene supplements alter the expression of proteins marking the status of proliferation, differentiation, cell regulation and apoptosis in high-risk tissue.
baseline and 6 months
No
Peter H Gann, MD, ScD
Principal Investigator
University of Illinois
United States: Food and Drug Administration
2005-0828
NCT01443026
February 2006
April 2009
Name | Location |
---|---|
Northwestern Memorial Hospital | Chicago, Illinois 60611 |
Jesse Brown VA Medical Center | Chicago, Illinois 60612 |